Key Details
Annual ROE
-169.75%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 15, 2022Recent annual earnings:
Mar 31, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 12, 2023Analyst ratings
Recent major analysts updates
18 Oct '23 Wedbush
Neutral17 Aug '23 HC Wainwright & Co.
Buy16 Aug '23 Stifel
Hold01 Aug '23 HC Wainwright & Co.
Buy01 June '23 Stifel
Hold31 May '23 HC Wainwright & Co.
Buy05 Apr '23 Stifel
Hold05 Apr '23 HC Wainwright & Co.
Buy22 Aug '22 HC Wainwright & Co.
Buy11 Aug '22 BTIG
BuyScreeners with FRLN included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Freeline Therapeutics Holdings doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
FRLN
Zacks Investment Research23 November 2023
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024.
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
FRLN
GlobeNewsWire08 August 2023
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update.
Freeline to Participate in Upcoming Investor Conferences
FRLN
GlobeNewsWire31 July 2023
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company will be participating in two upcoming investor conferences in August. Details are as follows:
New Strong Buy Stocks for July 14
FRLN
Zacks Investment Research14 July 2023
LE, ING, PD, FRLN and SUNW have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2023.
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
FRLN
Zacks Investment Research13 June 2023
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
FAQ
- What is the primary business of Freeline Therapeutics Holdings?
- What is the ticker symbol for Freeline Therapeutics Holdings?
- Does Freeline Therapeutics Holdings pay dividends?
- What sector is Freeline Therapeutics Holdings in?
- What industry is Freeline Therapeutics Holdings in?
- What country is Freeline Therapeutics Holdings based in?
- When did Freeline Therapeutics Holdings go public?
- Is Freeline Therapeutics Holdings in the S&P 500?
- Is Freeline Therapeutics Holdings in the NASDAQ 100?
- Is Freeline Therapeutics Holdings in the Dow Jones?
- When was Freeline Therapeutics Holdings's last earnings report?
- When does Freeline Therapeutics Holdings report earnings?
- Should I buy Freeline Therapeutics Holdings stock now?
What is the primary business of Freeline Therapeutics Holdings?
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
What is the ticker symbol for Freeline Therapeutics Holdings?
The ticker symbol for Freeline Therapeutics Holdings is NASDAQ:FRLN
Does Freeline Therapeutics Holdings pay dividends?
No, Freeline Therapeutics Holdings does not pay dividends
What sector is Freeline Therapeutics Holdings in?
Freeline Therapeutics Holdings is in the Healthcare sector
What industry is Freeline Therapeutics Holdings in?
Freeline Therapeutics Holdings is in the Biotechnology industry
What country is Freeline Therapeutics Holdings based in?
Freeline Therapeutics Holdings is headquartered in United Kingdom
When did Freeline Therapeutics Holdings go public?
Freeline Therapeutics Holdings's initial public offering (IPO) was on 07 August 2020
Is Freeline Therapeutics Holdings in the S&P 500?
No, Freeline Therapeutics Holdings is not included in the S&P 500 index
Is Freeline Therapeutics Holdings in the NASDAQ 100?
No, Freeline Therapeutics Holdings is not included in the NASDAQ 100 index
Is Freeline Therapeutics Holdings in the Dow Jones?
No, Freeline Therapeutics Holdings is not included in the Dow Jones index
When was Freeline Therapeutics Holdings's last earnings report?
Freeline Therapeutics Holdings's most recent earnings report was on 15 November 2022
When does Freeline Therapeutics Holdings report earnings?
The date for Freeline Therapeutics Holdings's next earnings report has not been announced yet
Should I buy Freeline Therapeutics Holdings stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions